Michael Redman, Chief Operating Officer and EVP
Austin, TX
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. The Company’s lead product candidate, OncoprexTM, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells using a novel formulation containing the TUSC2 suppressor gene. This suppressor gene is reduced or absent in over 80% of lung cancers of all histologies. In particular, Oncoprex modulates the immune response against cancer cells and has shown clinical evidence of converting “cold” tumors (resistant to treatment) to “hot” tumors. Cold tumors are responsible for tumor progression in several cancers, especially NSCLC. OncoprexTM received Fast Track designation in combination with osimertinib (Tagrisso®) in 2020. Genprex will also be conducting a Phase I/II clinical trial in combination with Pembroluzimab (Keytruda®).

By using this website you agree to accept our Privacy Policy and Terms & Conditions